With a high mortality rate, breast cancer is one of the most common types of cancer among women. In case of a positive diagnosis, modern medicine proposes the use of surgery for total eradication of the tumor, or chemotherapy in case of spread of cancer cells. However, a team of researchers is working on a new cure for this disease. Let's find out later in this article.
Breast cancer originates in breast tissue, causing a mutation in the breast cells, causing them to multiply rapidly and anarchically. Favored by various factors, such as age, genetic predisposition, hormonal disorders or overweight, it triggers the appearance of several symptoms, namely: deformity of the breast, unexplained bleeding or bleeding of the nipple, presence of Balls in the breast or ganglions under the armpits, etc.
Once the diagnosis is made, people with this cancer should be immediately taken care of to minimize the spread of tumors (metastasis), thus increasing the chances of recovery and reducing the risk of sequelae and recurrences.
In addition to the treatments offered by modern medicine, a team of scientists would be studying a new cure for this disease. Let's find out!
A new discovery in the field of cancer treatment
During the 10th European Breast Cancer Conference (EBCC-10) in Amsterdam, Nigel Bundred, professor of surgical oncology at the University of Manchester and the University Hospital Center of the South Manchester NHS Foundation Trust, Revealed that he and his team have tested the effectiveness of combining two drugs in the fight against breast cancer tumors: trastuzumab- generic form of Herceptin - and laptinib.
Generally used during chemotherapy, these two drugs used together for the first time, eliminated certain types of breast cancer cells in 11 days, without resorting to surgery or chemotherapy.
The results of the study
This study was conducted on 257 women with HER2-positive breast cancer. This particular form of breast cancer represents between 15 and 20% of all cases of this type of cancer. It is caused by hyperactivity of the HER2 gene (Human Epidermal Growth Factor Receptor 2), responsible for the regulation and control of cell proliferation.
Shortly after their diagnosis and before undergoing surgery, these women were divided into three groups. A control group that will not follow any treatment, a second who will be treated with trastuzumab and the latter with laptinib. In the course of the study, the researchers decided to test the effects of a combination of the two drugs, and thus added trastuzumab to the treatment of the third group.
After 11 days, 7 of the 66 women (11%) in the third group showed cancer cells disappeared and 11 others (17%) saw their tumor sizes decline considerably. Concerning the group of trastuzumab (Herceptin), only 3% of the women showed a narrowing of the cells and no disappearance of the disease. Thus, it has been clearly demonstrated that the combination of these two drugs allows a better and faster response, compared to their separate use. Indeed, according to Cancer Research UK, the current treatments against this type of breast cancer make it possible to have good results after 3 to 4 months.
It is true that the license to use Herceptin is limited to use in the context of chemotherapy, but the results of this study may help to change this.
Moreover, the optimistic and promising results that it has obtained, could represent the beginning of a new era in the treatment of breast cancer. More efforts are needed and more research is needed in order to save the lives of hundreds of women around the world, enabling them to deal with the disease quickly without having to go through the operating room Or to endure the more than unpleasant side effects of chemotherapy, their physical and moral health and appearance.